(Street) SAN

(City)

FRANCISCO

CA

(State)

1. Name and Address of Reporting Person*

94104

(Zip)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Vac:gtc1, 2.0.10
CTATEMENT OF CHANCES IN DENETICIAL OWNEDSHIP
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPF	ROVAL
OMB Number:	3235-0287
Estimated average b	urden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruc	tion 1(b).			Filed							ies Exchange npany Act of		934					
1. Name and Address of Reporting Person* <u>BVF PARTNERS L P/IL</u>				2. Issuer Name and Ticker or Trading Symbol GLYCOMIMETICS INC [GLYC]							neck all app Direc	ctor	ng Pe	(10% C	wner			
(Last) (First) (Middle) 44 MONTGOMERY ST. 40TH FL				3. Date of Earliest Transaction (Month/Day/Year) 10/30/2020							Office below	er (give title w)		Other (below)	(specify			
(Street) SAN FRANCI	sco CA	A 9)4104		4. If A	mer	ndment,	Date o	f Origina	al Filed	d (Month/Day	/Year)	Lin	e) Form	r Joint/Grou n filed by On n filed by Mo on	e Rep	oorting Pers	son
(City)	(St	ate) (2	Zip)															
		Table	I - No	n-Deriva	tive S	Sec	urities	s Acq	uired,	Dis	posed of,	or Be	neficia	ally Own	ed			
Date			2. Transac Date (Month/Da	Execution Date,		Transaction		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			d Securi Benefi	cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)	Price	Transa (Instr.	action(s) 3 and 4)			, ,
		001 par value ⁽¹⁾		10/30/2					P		666,385	A	\$2.7	_	06,320	_	D ⁽²⁾	
		001 par value ⁽¹⁾		10/30/2					P		250,755	A	\$2.7		3,206,195		D ⁽³⁾	
Common	Stock, \$0.0	001 par value ⁽¹⁾	hla II	10/30/2			wition.	Λ	P incal F)ion	15,472	A Dom	\$2.7		14,363 	<u> </u>	D ⁽⁴⁾	
		Id									osed of, o convertible				u			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed on Date, /Day/Year)	4. Transa Code (I 8)		n of Deriv Secu Acqu (A) o Dispo	osed) r. 3, 4	6. Date Expirati (Month/	ion Da	ite ear)	7. Title a Amount Securitie Underlyi Derivativ Security 3 and 4)	of es ng re	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	OI N Of	umber					
	nd Address of ARTNER	Reporting Person*	•															
(Last) 44 MON 40TH FL	TGOMER	(First) Y ST.	(Mid	ddle)														
(Street) SAN FRANCI	SCO	CA	941	104														
(City)		(State)	(Zip)														
		Reporting Person*		ID L P														
(Last) 44 MON 40TH FL	TGOMER	(First) Y STREET	(Mid	ddle)														

(Last)	(First)	(Middle)
	ERY ST., 40TH F	
(Street) SAN		
FRANCISCO	CA	94104
(City)	(State)	(Zip)
	ss of Reporting Perso DLOGY VALU	JE FUND II LP
(Last)	(First)	(Middle)
44 MONTGOM	ERY STREET	
40TH FL		
(Street)		
SAN FRANCISCO	CA	94104
1 IVAINCISCO		
(City)	(State)	(Zip)
1. Name and Addres	ss of Reporting Perso	n*
BVF II GP LI	<u>LC</u>	
(Last)	(First)	(Middle)
	ERY ST., 40TH F	
(Street)		
SAN FRANCISCO	CA	94104
	(State)	
1. Name and Addres Biotechnolog (Last)	ss of Reporting Perso y Value Tradin (First)	n* g Fund OS LP (Middle)
1. Name and Addres Biotechnolog (Last)	ss of Reporting Perso <u>y Value Tradin</u>	n* g Fund OS LP (Middle)
1. Name and Addres Biotechnolog (Last)	ss of Reporting Perso y Value Tradin (First)	n* g Fund OS LP (Middle)
I. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND	ss of Reporting Perso y Value Tradin (First)	n* g Fund OS LP (Middle)
I. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street)	ss of Reporting Perso y Value Tradin (First) GLAND HOUSE	n* g Fund OS LP (Middle)
I. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND	ss of Reporting Perso y Value Tradin (First) GLAND HOUSE	n* g Fund OS LP (Middle)
L. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City)	ss of Reporting Perso y Value Tradin (First) GLAND HOUSE	m* g Fund OS LP (Middle) KY1-1104 (Zip)
L. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City)	ss of Reporting Perso y Value Tradin (First) (GLAND HOUSE E9 (State)	m* g Fund OS LP (Middle) KY1-1104 (Zip)
I. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF Partners	ss of Reporting Perso y Value Tradin (First) GLAND HOUSE E9 (State) ss of Reporting Perso OS Ltd.	m* g Fund OS LP (Middle) KY1-1104 (Zip)
L. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) L. Name and Addres BVF Partners (Last)	ss of Reporting Person y Value Trading (First) (GLAND HOUSE E9 (State) ss of Reporting Person OS Ltd. (First)	m* g Fund OS LP (Middle) KY1-1104 (Zip) m* (Middle)
L. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) L. Name and Addres BVF Partners (Last)	ss of Reporting Perso y Value Tradin (First) GLAND HOUSE E9 (State) ss of Reporting Perso OS Ltd.	m* g Fund OS LP (Middle) KY1-1104 (Zip) m* (Middle)
L. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) L. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street)	ss of Reporting Person y Value Trading (First) (GLAND HOUSE E9 (State) ss of Reporting Person OS Ltd. (First)	m* g Fund OS LP (Middle) KY1-1104 (Zip) m* (Middle)
L. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) L. Name and Addres BVF Partners (Last) P.O. BOX 309 U (Street) GRAND	ss of Reporting Person y Value Trading (First) (GLAND HOUSE E9 (State) ss of Reporting Person OS Ltd. (First)	m* g Fund OS LP (Middle) KY1-1104 (Zip) m* (Middle)
L. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) L. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street)	(First) (State)	m* g Fund OS LP (Middle) KY1-1104 (Zip) m* (Middle)
L. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) L. Name and Addres BVF Partners (Last) P.O. BOX 309 U (Street) GRAND	(First) (State)	m* g Fund OS LP (Middle) KY1-1104 (Zip) m* (Middle)
I. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) (City)	ss of Reporting Perso y Value Tradin (First) (GLAND HOUSE E9 (State) ss of Reporting Perso OS Ltd. (First) (GLAND HOUSE	(Middle) KY1-1104 (Zip) n* (Middle)
I. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address	es of Reporting Perso y Value Tradin (First) (GLAND HOUSE E9 (State) es of Reporting Perso of OS Ltd. (First) (GLAND HOUSE E9 (State)	(Middle) KY1-1104 (Zip) n* (Middle)
I. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF GP HOI (Last)	ss of Reporting Perso y Value Tradin (First) (GLAND HOUSE E9 (State) ss of Reporting Perso OS Ltd. (First) (GLAND HOUSE E9 (State) ss of Reporting Perso CLDINGS LLC (First)	(Middle) (Middle) (XY1-1104 (Zip) (Middle) (XY1-1104 (Zip) (Middle)
I. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF GP HOI (Last)	E9 (State) So of Reporting Person (State) (First) (State) So of Reporting Person (State) (First) (GLAND HOUSE E9 (State) (State) E9 (State) So of Reporting Person (State) So of Reporting Person (State)	(Middle) (Middle) (XY1-1104 (Zip) (Middle) (XY1-1104 (Zip) (Middle)
I. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF GP HOI (Last) 44 MONTGOM	ss of Reporting Perso y Value Tradin (First) (GLAND HOUSE E9 (State) ss of Reporting Perso OS Ltd. (First) (GLAND HOUSE E9 (State) ss of Reporting Perso CLDINGS LLC (First)	(Middle) (Middle) (XY1-1104 (Zip) (Middle) (XY1-1104 (Zip) (Middle)
I. Name and Address Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) I. Name and Address BVF GP HOI (Last)	ss of Reporting Perso y Value Tradin (First) (GLAND HOUSE E9 (State) ss of Reporting Perso OS Ltd. (First) (GLAND HOUSE E9 (State) ss of Reporting Perso CLDINGS LLC (First)	(Middle) (Middle) (XY1-1104 (Zip) (Middle) (XY1-1104 (Zip) (Middle)

(City)	(State)	(Zip)							
1. Name and Address of Reporting Person* BVF INC/IL									
(Last)	(First)	(Middle)							
44 MONTGOMERY STREET									
40TH FL									
(Street) SAN FRANCISCO	CA	94104							
(City)	(State)	(Zip)							
1. Name and Address LAMPERT MA									
(Last)	(First)	(Middle)							
44 MONTGOME	RY STREET								
40TH FL									
(Street) SAN FRANCISCO	CA	94104							
(City)	(State)	(Zip)							

Explanation of Responses

- 1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- 2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- 3. Securities owned directly by BVF2. As the general partner of BVF2 GP, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- 4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	11/03/2020
Biotechnology Value Fund, L.P., By: BVF Partners L.P., its investment manager, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	<u>11/03/2020</u>
BVF I GP LLC, By: BVF GP HOLDINGS LLC, its sole member, By: /s/ Mark N. Lampert, Chief Executive Officer	<u>11/03/2020</u>
Biotechnology Value Fund II, L.P., By: BVF Partners L.P., its investment manager, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	<u>11/03/2020</u>
BVF II GP LLC, By: BVF GP HOLDINGS LLC, its sole member, By: /s/ Mark N. Lampert, Chief Executive Officer	11/03/2020
BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	<u>11/03/2020</u>
Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment	11/03/2020

manager, BVF Inc., its general partner, By: /s/ Mark N.
Lampert, President

BVF GP Holdings LLC, By:

/s/ Mark N. Lampert, Chief 11/03/2020

Executive Officer

/s/ Mark N. Lampert

BVF Inc., By: /s/ Mark N. <u>Lampert, President</u>

11/03/2020

11/03/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.